Literature DB >> 25136078

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Christopher R Cogle1, Elizabeth Wise1, Amy M Meacham1, Claudia Zierold1, Jay H Traverse1, Timothy D Henry1, Emerson C Perin1, James T Willerson1, Stephen G Ellis1, Marjorie Carlson1, David X M Zhao1, Roberto Bolli1, John P Cooke1, Saif Anwaruddin1, Aruni Bhatnagar1, Maria da Graca Cabreira-Hansen1, Maria B Grant1, Dejian Lai1, Lem Moyé2, Ray F Ebert1, Rachel E Olson1, Shelly L Sayre1, Ivonne H Schulman1, Raphael C Bosse1, Edward W Scott1, Robert D Simari1, Carl J Pepine1, Doris A Taylor1.   

Abstract

RATIONALE: Bone marrow (BM) cell therapy for ischemic heart disease (IHD) has shown mixed results. Before the full potency of BM cell therapy can be realized, it is essential to understand the BM niche after acute myocardial infarction (AMI).
OBJECTIVE: To study the BM composition in patients with IHD and severe left ventricular (LV) dysfunction. METHODS AND
RESULTS: BM from 280 patients with IHD and LV dysfunction were analyzed for cell subsets by flow cytometry and colony assays. BM CD34(+) cell percentage was decreased 7 days after AMI (mean of 1.9% versus 2.3%-2.7% in other cohorts; P<0.05). BM-derived endothelial colonies were significantly decreased (P<0.05). Increased BM CD11b(+) cells associated with worse LV ejection fraction (LVEF) after AMI (P<0.05). Increased BM CD34(+) percentage associated with greater improvement in LVEF (+9.9% versus +2.3%; P=0.03, for patients with AMI and +6.6% versus -0.02%; P=0.021 for patients with chronic IHD). In addition, decreased BM CD34(+) percentage in patients with chronic IHD correlated with decrement in LVEF (-2.9% versus +0.7%; P=0.0355).
CONCLUSIONS: In this study, we show a heterogeneous mixture of BM cell subsets, decreased endothelial colony capacity, a CD34+ cell nadir 7 days after AMI, a negative correlation between CD11b percentage and postinfarct LVEF, and positive correlation of CD34 percentage with change in LVEF after cell therapy. These results serve as a possible basis for the small clinical improvement seen in autologous BM cell therapy trials and support selection of potent cell subsets and reversal of comorbid BM impairment. CLINICAL TRIAL REGISTRATIONS URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00684021, NCT00684060, and NCT00824005.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  angiogenesis effect; blood cells; bone marrow; myocardial infarction; stem cells

Mesh:

Substances:

Year:  2014        PMID: 25136078      PMCID: PMC4358751          DOI: 10.1161/CIRCRESAHA.115.304353

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  29 in total

1.  Rapid and large increase of the frequency of circulating endothelial colony-forming cells (ECFCs) generating late outgrowth endothelial cells in patients with acute myocardial infarction.

Authors:  Margherita Massa; Rita Campanelli; Elisa Bonetti; Maurizio Ferrario; Barbara Marinoni; Vittorio Rosti
Journal:  Exp Hematol       Date:  2008-11-13       Impact factor: 3.084

2.  Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Bojan Vrtovec; Gregor Poglajen; Luka Lezaic; Matjaz Sever; Aljaz Socan; Dragoslav Domanovic; Peter Cernelc; Guillermo Torre-Amione; François Haddad; Joseph C Wu
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

3.  Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.

Authors:  Gerard J Madlambayan; Jason M Butler; Koji Hosaka; Marda Jorgensen; Dongtao Fu; Steven M Guthrie; Anitha K Shenoy; Adam Brank; Kathryn J Russell; Jaclyn Otero; Dietmar W Siemann; Edward W Scott; Christopher R Cogle
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

4.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

5.  Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Authors:  Douglas W Losordo; Timothy D Henry; Charles Davidson; Joon Sup Lee; Marco A Costa; Theodore Bass; Farrell Mendelsohn; F David Fortuin; Carl J Pepine; Jay H Traverse; David Amrani; Bruce M Ewenstein; Norbert Riedel; Kenneth Story; Kerry Barker; Thomas J Povsic; Robert A Harrington; Richard A Schatz
Journal:  Circ Res       Date:  2011-07-07       Impact factor: 17.367

6.  Stem cells. Could it be TIME to abandon BMCs?

Authors:  Alexandra King
Journal:  Nat Rev Cardiol       Date:  2012-11-20       Impact factor: 32.419

7.  Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.

Authors:  Claudia Zierold; Marjorie A Carlson; Udo C Obodo; Elizabeth Wise; Victor A Piazza; Marshall W Meeks; Rachel W Vojvodic; Sarah Baraniuk; Timothy D Henry; Adrian P Gee; Stephen G Ellis; Lemuel A Moyé; Carl J Pepine; Christopher R Cogle; Doris A Taylor
Journal:  Am Heart J       Date:  2011-12       Impact factor: 4.749

8.  Changes in the frequency and in vivo vessel-forming ability of rhesus monkey circulating endothelial colony-forming cells across the lifespan (birth to aged).

Authors:  W Chris Shelley; Alyssa C Leapley; Lan Huang; Paul J Critser; Pingyu Zeng; Daniel Prater; David A Ingram; Alice F Tarantal; Mervin C Yoder
Journal:  Pediatr Res       Date:  2011-12-21       Impact factor: 3.756

9.  CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN-γ-dependent autophagy.

Authors:  Gang Zhao; Shijun Wang; Zhen Wang; Aijun Sun; Xiangdong Yang; Zhaohui Qiu; Chaoneng Wu; Wenbin Zhang; Hua Li; Youen Zhang; Jingjing Zhao; Yunzeng Zou; Junbo Ge
Journal:  Int J Cardiol       Date:  2012-11-13       Impact factor: 4.164

10.  Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Authors:  Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

View more
  26 in total

1.  Predictive Value of Circulating Progenitor Cells in Acute Coronary Syndrome: Implications for Treatment.

Authors:  Courtney Premer; Ivonne Hernandez Schulman
Journal:  Circ Res       Date:  2018-05-25       Impact factor: 17.367

Review 2.  Potential clinical benefits of cell therapy in coronary heart disease: an update.

Authors:  Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone Marrow.

Authors:  Taku Nakashima; Tianju Liu; Biao Hu; Zhe Wu; Matthew Ullenbruch; Keitaro Omori; Lin Ding; Noboru Hattori; Sem H Phan
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

4.  Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes.

Authors:  Ayman Samman Tahhan; Muhammad Hammadah; Mohamad Raad; Zakaria Almuwaqqat; Ayman Alkhoder; Pratik B Sandesara; Heval Mohamed-Kelli; Salim S Hayek; Jeong Hwan Kim; Wesley T O'Neal; Matthew L Topel; Aubrey J Grant; Nabil Sabbak; Robert E Heinl; Mohamad Mazen Gafeer; Malik Obideen; Belal Kaseer; Nasser Abdelhadi; Yi-An Ko; Chang Liu; Iraj Hesaroieh; Ernestine A Mahar; Viola Vaccarino; Edmund K Waller; Arshed A Quyyumi
Journal:  Circ Res       Date:  2018-03-07       Impact factor: 17.367

5.  Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Authors:  Ariadna Contreras; Aaron F Orozco; Micheline Resende; Robert C Schutt; Jay H Traverse; Timothy D Henry; Dejian Lai; John P Cooke; Roberto Bolli; Michelle L Cohen; Lem Moyé; Carl J Pepine; Phillip C Yang; Emerson C Perin; James T Willerson; Doris A Taylor
Journal:  Basic Res Cardiol       Date:  2016-11-23       Impact factor: 17.165

6.  Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Authors:  Aruni Bhatnagar; Roberto Bolli; Brian H Johnstone; Jay H Traverse; Timothy D Henry; Carl J Pepine; James T Willerson; Emerson C Perin; Stephen G Ellis; David X M Zhao; Phillip C Yang; John P Cooke; Robert C Schutt; Barry H Trachtenberg; Aaron Orozco; Micheline Resende; Ray F Ebert; Shelly L Sayre; Robert D Simari; Lem Moyé; Christopher R Cogle; Doris A Taylor
Journal:  Am Heart J       Date:  2016-07-06       Impact factor: 4.749

Review 7.  Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review.

Authors:  Patricia K Nguyen; June-Wha Rhee; Joseph C Wu
Journal:  JAMA Cardiol       Date:  2016-10-01       Impact factor: 14.676

8.  Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.

Authors:  Mariann Gyöngyösi; Wojciech Wojakowski; Patricia Lemarchand; Ketil Lunde; Michal Tendera; Jozef Bartunek; Eduardo Marban; Birgit Assmus; Timothy D Henry; Jay H Traverse; Lemuel A Moyé; Daniel Sürder; Roberto Corti; Heikki Huikuri; Johanna Miettinen; Jochen Wöhrle; Slobodan Obradovic; Jérome Roncalli; Konstantinos Malliaras; Evgeny Pokushalov; Alexander Romanov; Jens Kastrup; Martin W Bergmann; Douwe E Atsma; Axel Diederichsen; Istvan Edes; Imre Benedek; Theodora Benedek; Hristo Pejkov; Noemi Nyolczas; Noemi Pavo; Jutta Bergler-Klein; Imre J Pavo; Christer Sylven; Sergio Berti; Eliano P Navarese; Gerald Maurer
Journal:  Circ Res       Date:  2015-02-19       Impact factor: 17.367

9.  Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Authors:  Doris A Taylor; Emerson C Perin; James T Willerson; Claudia Zierold; Micheline Resende; Marjorie Carlson; Belinda Nestor; Elizabeth Wise; Aaron Orozco; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Jay H Traverse; John P Cooke; Robert C Schutt; Aruni Bhatnagar; Maria B Grant; Dejian Lai; Brian H Johnstone; Shelly L Sayre; Lem Moyé; Ray F Ebert; Roberto Bolli; Robert D Simari; Christopher R Cogle
Journal:  Cell Transplant       Date:  2015-11-19       Impact factor: 4.064

Review 10.  Stem cell therapy for heart failure: Ensuring regenerative proficiency.

Authors:  Andre Terzic; Atta Behfar
Journal:  Trends Cardiovasc Med       Date:  2016-01-28       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.